These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35524725)

  • 21. Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.
    Mota M; Sweha SR; Pun M; Natarajan SK; Ding Y; Chung C; Hawes D; Yang F; Judkins AR; Samajdar S; Cao X; Xiao L; Parolia A; Chinnaiyan AM; Venneti S
    Proc Natl Acad Sci U S A; 2023 May; 120(18):e2221175120. PubMed ID: 37094128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas.
    Algranati D; Oren R; Dassa B; Fellus-Alyagor L; Plotnikov A; Barr H; Harmelin A; London N; Ron G; Furth N; Shema E
    Elife; 2024 Aug; 13():. PubMed ID: 39093942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
    Dono A; Takayasu T; Ballester LY; Esquenazi Y
    J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma.
    Wang SS; Pandey K; Watson KA; Abbott RC; Mifsud NA; Gracey FM; Ramarathinam SH; Cross RS; Purcell AW; Jenkins MR
    Mol Ther Oncolytics; 2023 Sep; 30():167-180. PubMed ID: 37674626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of diffuse intrinsic pontine glioma mouse models by brainstem-targeted in utero electroporation.
    Patel SK; Hartley RM; Wei X; Furnish R; Escobar-Riquelme F; Bear H; Choi K; Fuller C; Phoenix TN
    Neuro Oncol; 2020 Mar; 22(3):381-392. PubMed ID: 31638150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
    Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
    Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone H3 K27M-mediated regulation of cancer cell stemness and differentiation in diffuse midline glioma.
    Sharma M; Barravecchia I; Magnuson B; Ferris SF; Apfelbaum A; Mbah NE; Cruz J; Krishnamoorthy V; Teis R; Kauss M; Koschmann C; Lyssiotis CA; Ljungman M; Galban S
    Neoplasia; 2023 Oct; 44():100931. PubMed ID: 37647805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiotherapy and radio-sensitization in H3
    Liu C; Kuang S; Wu L; Cheng Q; Gong X; Wu J; Zhang L
    CNS Neurosci Ther; 2023 Jul; 29(7):1721-1737. PubMed ID: 37157237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
    Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM
    J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PRC2-independent actions of H3.3K27M in embryonic stem cell differentiation.
    Cohen LRZ; Kaffe B; Deri E; Leibson C; Nissim-Rafinia M; Maman M; Harpaz N; Ron G; Shema E; Meshorer E
    Nucleic Acids Res; 2023 Feb; 51(4):1662-1673. PubMed ID: 36156096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases.
    Zheng L; Gong J; Yu T; Zou Y; Zhang M; Nie L; Chen X; Yue Q; Liu Y; Mao Q; Zhou Q; Chen N
    Am J Surg Pathol; 2022 Jun; 46(6):863-871. PubMed ID: 35416795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
    Vuong HG; Ngo TNM; Le HT; Dunn IF
    J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
    Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
    Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
    Grassl N; Sahm K; Süße H; Poschke I; Bunse L; Bunse T; Boschert T; Mildenberger I; Rupp AK; Ewinger MP; Lanz LM; Denk M; Tabatabai G; Ronellenfitsch MW; Herrlinger U; Glas M; Krex D; Vajkoczy P; Wick A; Harting I; Sahm F; von Deimling A; Bendszus M; Wick W; Platten M
    Neurol Res Pract; 2023 Oct; 5(1):55. PubMed ID: 37853454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.
    Dhar S; Gadd S; Patel P; Vaynshteyn J; Raju GP; Hashizume R; Brat DJ; Becher OJ
    Acta Neuropathol Commun; 2022 Apr; 10(1):47. PubMed ID: 35395831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
    Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
    Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
    Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
    Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 40. The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas.
    Anderson JL; Muraleedharan R; Oatman N; Klotter A; Sengupta S; Waclaw RR; Wu J; Drissi R; Miles L; Raabe EH; Weirauch ML; Fouladi M; Chow LM; Hoffman L; DeWire M; Dasgupta B
    Neuro Oncol; 2017 Aug; 19(8):1068-1078. PubMed ID: 28339768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.